Stock Events

Stock Events

Abivax 

€107
0
+€0+0% Friday 19:47

Statistics

Day High
109
Day Low
105
52W High
120
52W Low
4.54
Volume
366
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25MayExpected
Q4 2025
Next
-1.17
-1.05
-0.92
-0.79
Expected EPS
-0.7929079780015681
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2X10.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that competes with Abivax in the development of antiviral drugs, including treatments for HIV, which is a focus area for Abivax.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is involved in creating antiviral treatments and therapies for infectious diseases, competing directly with Abivax's efforts in HIV and other viral infections.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. is a global healthcare company that develops antiviral drugs, including therapies for HIV/AIDS, positioning it as a competitor to Abivax.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline plc focuses on developing and marketing vaccines and medications for HIV, directly competing with Abivax's research and development in HIV treatments.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, works on developing treatments for infectious diseases, including HIV, making it a competitor to Abivax.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie Inc. competes in the area of antiviral research, with a focus on therapies for HIV, hepatitis, and other viral infections, areas that Abivax is also targeting.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products, including antiviral drugs, competing with Abivax in the infectious disease space.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb is engaged in the discovery and development of prescription medicines for various diseases, including HIV/AIDS, making it a direct competitor to Abivax.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, Inc. is known for its work in biotechnology and the development of medicines for infectious diseases, competing with Abivax in the biopharmaceutical field.
Novartis
NVS
Mkt Cap297.32B
Novartis AG is a global healthcare company that researches and develops treatments for a wide range of diseases, including viral infections, competing with Abivax in the pharmaceutical and healthcare market.

About

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Show more...
CEO
Mr. Didier Blondel
Employees
69
Country
DE
ISIN
US00370M1036

Listings

F
DE
2X10.F
STU
DE
2X10.STU
STU
DE
2X1.STU
XETRA
DE
2X1.XETRA

0 Comments

Share your thoughts

FAQ

What is Abivax stock price today?▼
The current price of 2X10.STU is €107 EUR — it has increased by +0% in the past 24 hours. Watch Abivax stock price performance more closely on the chart.
What is Abivax stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Abivax stocks are traded under the ticker 2X10.STU.
Is Abivax stock price growing?▼
2X10.STU stock has risen by +9.74% compared to the previous week, the month change is a +10.31% rise, over the last year Abivax has showed a +2,147.9% increase.
When is the next Abivax earnings date?▼
Abivax is going to release the next earnings report on May 25, 2026.
What were Abivax earnings last quarter?▼
2X10.STU earnings for the last quarter are -1.05 EUR per share, whereas the estimation was -1.17 EUR resulting in a +10.39% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Abivax have?▼
As of April 11, 2026, the company has 69 employees.
When did Abivax complete a stock split?▼
Abivax has not had any recent stock splits.
Where is Abivax headquartered?▼
Abivax is headquartered in Paris, DE.